You just read:

Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China

News provided by

Cellular Biomedicine Group

Jun 17, 2019, 07:00 ET